RESEARCH AND DEVELOPMENT
Winning Research & Development
We’ve long believed that world-class R&D infrastructure and capabilities were the key drivers of value creation and sustainable growth. Consequently, our strong emphasis, deep focus, and industry-leading financial commitment towards R&D, has enabled us to set up one of the most comprehensive R&D facilities in the world with end-to-end discovery research and New Chemical Entity (NCE) development competencies. Our state-of-the-art, multidisciplinary R&D facilities are located across India, USA, UK and UAE.
Over the years, our strategic decision to focus on New Drug Discovery, Recombinant Biopharmaceuticals, Novel Drug Delivery and Generics, has been highly successful, satisfying and encouraging. With a product pipeline that focuses on less competitive and difficult to replicate products, we have built a strong Intellectual Property (IP) base ﬁling patents and developing products for Abbreviated New Drug Applications (ANDAs) for the US and European markets. Till date, we have filed 3,037 patents cumulatively, and have been granted 628 patents.
Winning the War on AMR
The globally rising concern over AMR (Antimicrobial Resistance) and the promising developments of our Drug Discovery Programme have placed us on the cusp of an extremely exciting phase in the quest for discovering new antibiotics.
Our over 2-decade long focus and efforts in developing novel antibiotics has resulted in 5 of our new drugs under development being accorded Qualified Infectious Disease Product (QIDP) status by US FDA, all of which have entered Phase III clinical stage. Being developed as novel antibiotics, all 5 drugs are expected to significantly help the global war against Antimicrobial Resistance (AMR) in the near future. The progress made has been shared, presented and published at various industry fora.